Methods for identifying compounds for the treatment of type 1 diabetes
The present invention provides methods of identifying candidate compounds for the treatment of type I diabetes comprising contacting pancreatic β cells with an amount of apolipoprotein CIII (“apoCIII”) effective to increase intracellular calcium concentration, in the presence of one or more test compounds, and identifying those test compounds that inhibit an apoCIII-induced increase in intracellular calcium concentration in the pancreatic β cells. The present invention also provides methods for treating patients with type I diabetes comprising administering to the patient an amount effective of an inhibitor of apoCIII to reduce apoCIII-induced increase in intracellular calcium concentration in pancreatic β cells.
1. A method for limiting pancreatic β cell apoptosis comprising administering to a patient with type I diabetes an amount effective of an inhibitor of human apoCIII to reduce apoCIII-induced increase in intracellular calcium concentration in pancreatic β cells, wherein the inhibitor is selected from the group consisting of an apoCIII-selective antibody, an antisense oligonucleotide directed against the apoCIII mRNA, and a small interfering RNA directed against the apoCIII mRNA.
2. The method of claim 1 wherein the patient has an increased blood serum level of human apoCIII.
3. The method of claim 1 , wherein the patient has an increased blood serum level of sialylated human apoCIII.
4. The method of claim 1 , wherein the inhibitor is an apoCIII-selective antibody.
5. The method of claim 1 , wherein the inhibitor is an antisense oligonucleotide directed against the apoCIII mRNA.
6. The method of claim 1 , wherein the inhibitor is a small interfering RNA directed against the apoCIII mRNA.